Navigation Links
SIGA Passes First Hurdle with Lassa Fever Antiviral ST-193

NEW YORK--(BUSINESS WIRE)--May 15, 2007 - SIGA Technologies, Inc. (NASDAQ: SIGA) announced today the successful results of a proof of concept guinea pig trial of its lead Lassa fever virus drug, ST-193.

This study was conducted under Biosafety Level 4 conditions at the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) by Dr. Kathleen Cashman under the supervision of Dr. Mary Guttieri, who has been working on various hemorrhagic fever viruses at USAMRIID for over 12 years. Strain 13 guinea pigs were challenged with a lethal dose of Lassa virus and treated with ST-193 once a day for 14 days. Administration with ST-193 resulted in significant reduction in mortality at the two doses tested, 80 mg/kg and 25 mg/kg (71% of the animals survived at the low dose), whereas all of the control animals and those treated with ribavirin succumbed to the disease within 20 days of the challenge. The disease course in these guinea pigs recapitulates what is seen in human Lassa fever infections, and SIGA expects that this model is one of the two animal models that will be required to fulfill the U.S. Food and Drug Administration's "Animal Efficacy Rule."

"This is a tremendous milestone for our research group," said Dr. Dennis E. Hruby, SIGA's Chief Scientific Officer. "This study should provide the basis for advancing this lead candidate into IND-enabling activities in the near future."

Lassa virus, considered a hemorrhagic fever virus due to some of its prominent symptoms, is one type of arenavirus. Arenaviruses are potential biological weapons agents due to their ease of dissemination, person-to-person transmissibility, and potential to cause widespread illness and death. Creating and deploying antiviral drugs targeting arenaviruses will enhance national and global security by acting as a significant deterrent and defense against the use of arenaviruses as bioterror weapons. Six separate arenav
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Senate Passes Drug-Safety Reforms to Prevent Future Vioxx-type Disasters; House Urged to Act on Strong Drug Safety Bill
2. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
3. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
4. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
5. Ablynx Announces Interim Results of First Nanobody Phase I Study of ALX-0081 (ANTI-VWF)
6. Advanced Life Sciences Announces Supplemental Efficacy Data from First Pivotal Phase 3 Pneumonia Clinical Trial
7. Advanced Life Sciences to Host Conference Call to Discuss Data From Cethromycins First of Two Phase 3 Pneumonia Trials
8. First Phase II Short-Term Study on Dapagliflozin Shows Results on Safety, Tolerability and Glycemic Markers in Subjects With Type 2 Diabetes
9. Advanced Cell Technology Develops First Human Embryonic Stem Cell Line without Destroying an Embryo
10. First Demonstration of nanoImmunology: a Nanomaterials-based Therapeutic Approach to Treat Allergy
11. First single breast cancer study to show significant survival benefit for women switching from tamoxifen to Arimidex
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: SIGA Passes First Hurdle with Lassa Fever Antiviral
(Date:12/19/2014)... DUBLIN , Dec. 18, 2014 Research ... announced the addition of the "Micro Market ... report to their offering. ... dermatological treatment is progressing steadily, which has resulted ... diagnostic devices market. The main purpose of these ...
(Date:12/19/2014)... Dec. 18, 2014  RESMED INC. (NYSE: RMD ... of fiscal year 2015 results on Thursday, January 22, 2015, ... release with ResMed,s results will be issued after 1:00 p.m. ... to discuss operating results and future outlook. The ... Pacific Time and the live webcast of the call can ...
(Date:12/19/2014)... , Dec. 19, 2014  Eli Lilly and ... Paris: FR0011184241 – ADOC) today announced a worldwide licensing ... BioChaperone Lispro, for treatment in people with type 1 ... proprietary BioChaperone® technology and is currently in Phase Ib ... Lispro with the goal of optimizing glucose levels during ...
Breaking Medicine Technology:Micro Market Monitor: North American Dermatology Diagnostic Devices Market 2Micro Market Monitor: North American Dermatology Diagnostic Devices Market 3ResMed To Announce Second Quarter 2015 Results 2Lilly and Adocia Announce Alliance to Co-Develop Ultra-Rapid Insulin Based on BioChaperone Technology 2Lilly and Adocia Announce Alliance to Co-Develop Ultra-Rapid Insulin Based on BioChaperone Technology 3
... ALR ), a global leader in enabling individuals to ... rapid diagnostics and health management, has declared a dividend of $3.00 ... ALR PR B).  The dividend will be paid ... equal to the quotient of (a) $3.00 divided by (b) 97% ...
... CVS Caremark Corporation (NYSE: CVS ) today ... will be making a presentation to investors at the ... 25, 2011. Mr. Merlo is scheduled to present at ... An audio webcast of the presentation will be broadcast ...
Cached Medicine Technology:
(Date:12/19/2014)... Wisconsin (PRWEB) December 19, 2014 After ... music performer is again returning to the stage to ... her husband for concert performances, and the successful tour ... was originally announced. , Visit Ticketability.com ... the newly-announced Detroit shows at fair prices. , Music ...
(Date:12/19/2014)... -- A new study suggests a possible link between ... and night sweats -- and higher rates of hip ... during menopause, affecting about 60 percent of women. The ... since they then face a higher risk of weakened ... exhibit moderate or severe menopausal symptoms are more likely ...
(Date:12/19/2014)... (HealthDay News) -- Prostaglandin analogue eye drops -- a ... risk of vision loss in patients with the eye ... by David Garway-Heath, of the Moorfields Eye Hospital and ... more than 500 people newly diagnosed with open-angle glaucoma ... one of the leading causes of blindness. About ...
(Date:12/17/2014)... This prestigious award is given ... made outstanding and innovative contributions to the physical ... private practice physical therapy by the Private Practice ... On behalf of Performance Physical Therapy, Michelle Collie ... Performance accepted the award at the Private Practice, ...
(Date:12/17/2014)... Crest Hill, IL (PRWEB) December 17, 2014 ... of 2015 Awards celebrate the best of the best ... States. The award is only given to communities and ... families through the SeniorAdvisor.com site. Of the nearly 100,000 ... with this award. Winners of the SeniorAdvisor.com Best of ...
Breaking Medicine News(10 mins):Health News:Garth Brooks Tickets for Joe Louis Arena: Ticketability.com Becomes a Popular Destination for Discount Tickets for Garth Brooks’ Detroit Concerts Set for February 27-28 2Health News:Severe Hot Flashes During Menopause May Raise Hip Fracture Risk Later: Study 2Health News:Study Supports Benefit of Widely Used Glaucoma Drug 2Health News:Performance Physical Therapy Awarded with Jayne L. Snyder Private Practice of the Year 2014 2Health News:The Inn at Willow Falls - Crest Hill, IL Wins 2015 Best of Assisted Living Award from SeniorAdvisor.com 2Health News:The Inn at Willow Falls - Crest Hill, IL Wins 2015 Best of Assisted Living Award from SeniorAdvisor.com 3
... a verdict of $10.2 million in a medical malpractice ... the death of his patient. With interest, the ... was achieved by New Jersey medical malpractice lawyer David ... trial lawyers in the areas of professional malpractice, wrongful ...
... Diego Skin Doctor Supports Well-Being of Those with Multiple Sclerosis , ... San Diego, CA ... lot of ways. His passion is to treat your skin with love, but ... the creams and gels, and into the hearts of the community. Dr. Gram ...
... and Washington DC (March 9th, 2009) Ecstasy may ... their memories more effectively by encouraging a feeling of ... of Psychopharmacology published today by SAGE. , Studies ... exposure therapy where the patient repeatedly recalls the ...
... Selects Desktop and Production Messaging Solutions for Significant Savings, ... ... Norcross, GA (PRWEB) March 8, ... (NasdaqCM: ESIC)(easylink.com), a global provider of comprehensive messaging services, ...
... to kick-start efforts to unlock therapeutic potential , , SATURDAY, ... will lift the eight-year ban on embryonic stem cell ... A White House ceremony is scheduled for late morning, ... the federal funding limits imposed by his predecessor, President ...
... ARBOR, Mich.---Revered in India as "holy powder," the marigold-colored ... to treat wounds, infections and other health problems. In ... main ingredient, curcumin, has burgeoned, as its astonishing array ... been revealed. , Yet little has been known ...
Cached Medicine News:Health News:$12 Million New Jersey Medical Malpractice Verdict for Wrongful Death of a 21-Year-Old Man After Having Wisdom Teeth Removed 2Health News:SKIN1 by Dr. Gram Cares About Skin and Community 2Health News:Ecstasy could help patients with post-traumatic stress disorder 2Health News:Ecstasy could help patients with post-traumatic stress disorder 3Health News:Email Fax Provider, EasyLink Services, Announces Prominent Bio-Pharma Signing 2Health News:Email Fax Provider, EasyLink Services, Announces Prominent Bio-Pharma Signing 3Health News:Obama to End Stem Cell Ban Monday 2Health News:Obama to End Stem Cell Ban Monday 3Health News:'Holy powder' ingredient makes membranes behave for better health 2
... is one of the world's ... with a 7 F introducer, ... is designed to lower the ... allow introduction in smaller, more ...
Tendril DX active-fixation leads allows for lower thresholds initially and during the lead maturation phase....
... Guidant Flextend lead is ... lead with an extendable/retractable ... helix design offers various ... permanent implantation in the ...
... is a low profile implantable bipolar ... stimulation of either the atrium or ... supplied with a screwdriver shape stylet ... lead. The ring tip and fixation ...
Medicine Products: